Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan
Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory fl...
Saved in:
| Published in | Exploratory research in clinical and social pharmacy Vol. 7; p. 100156 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier
01.09.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory flexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines during the pandemic. In this commentary, we discuss the regulatory flexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic.Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory flexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines during the pandemic. In this commentary, we discuss the regulatory flexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic. |
|---|---|
| AbstractList | Summary Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory flexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines during the pandemic. In this commentary, we discuss the regulatory flexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic. Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory flexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines during the pandemic. In this commentary, we discuss the regulatory flexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic.Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory flexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines during the pandemic. In this commentary, we discuss the regulatory flexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic. |
| ArticleNumber | 100156 |
| Author | Tshering, Dawa Chejor, Pelden |
| Author_xml | – sequence: 1 givenname: Dawa surname: Tshering fullname: Tshering, Dawa – sequence: 2 givenname: Pelden surname: Chejor fullname: Chejor, Pelden |
| BookMark | eNp9kUtrGzEUhUVJaNI0v6AbLbsZV9LoMdoUWvdlCARCmq3Qa2wZWXIlTWj-fcdxKE0XWd3Lued8Epw34CTl5AF4h9ECI8w_bBfF1rxfEETIrCDM-CtwTjgXHRGcn_yzn4HLWrcIISIkRQK9Bmc9G5jkGJ-Duxu_nqJuuTzAMfrfwYQYWvAV6uSgttbXCluGy-u71ZcOS3g_ayHNdzeVkNawbTzcz16_CxaGBD9vpqbTW3A66lj95dO8AD-_fb1d_uiurr-vlp-uOkvp0DrNjLTMGs5Hwzg1RmLaazYYiUbdY4atQz0TGNkRa4aocYIjIwQWlmksZH8BVkeuy3qr9iXsdHlQWQf1KOSyVrq0YKNXjPDeS69FbxwlVBqHHZFuHAkejaRiZn08svaT2XlnfWpFx2fQ55cUNmqd75UkA2VkmAHvnwAl_5p8bWoXqvUx6uTzVBXhkgjGJSKztT9abcm1Fj_-fQYjdShYbdVjwepQsDoWPKfkfykbmm4hH_4T4ovZPx-nrjU |
| CitedBy_id | crossref_primary_10_1186_s12889_024_21189_y |
| Cites_doi | 10.1056/NEJMp2031373 10.22270/ijdra.v6i2.243 10.1016/j.jsat.2020.108263 10.1177/0141076820930665 10.1016/S0140-6736(21)00993-4 10.4269/ajtmh.20-0259 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. 2022 The Authors 2022 |
| Copyright_xml | – notice: 2022 The Authors. – notice: 2022 The Authors 2022 |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1016/j.rcsop.2022.100156 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2667-2766 |
| ExternalDocumentID | oai_doaj_org_article_5263e9ea73bd4249bd1d29dff21fb947 PMC9284528 10_1016_j_rcsop_2022_100156 |
| GroupedDBID | 0R~ AAEDW AALRI AAXUO AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AITUG AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP CITATION EBS FDB GROUPED_DOAJ M~E OK1 ROL RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c448t-a5b9c5cb66fb564bb9143a58b90fa3151cd035710cf1a504bd760b7717c5a1793 |
| IEDL.DBID | DOA |
| ISSN | 2667-2766 |
| IngestDate | Wed Aug 27 01:29:37 EDT 2025 Thu Aug 21 14:08:17 EDT 2025 Fri Jul 11 03:23:28 EDT 2025 Tue Jul 01 02:04:52 EDT 2025 Thu Apr 24 22:59:51 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c448t-a5b9c5cb66fb564bb9143a58b90fa3151cd035710cf1a504bd760b7717c5a1793 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/5263e9ea73bd4249bd1d29dff21fb947 |
| PMID | 35859611 |
| PQID | 2692756902 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5263e9ea73bd4249bd1d29dff21fb947 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9284528 proquest_miscellaneous_2692756902 crossref_primary_10_1016_j_rcsop_2022_100156 crossref_citationtrail_10_1016_j_rcsop_2022_100156 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Exploratory research in clinical and social pharmacy |
| PublicationYear | 2022 |
| Publisher | Elsevier |
| Publisher_xml | – name: Elsevier |
| References | Drug Regulatory Authority (10.1016/j.rcsop.2022.100156_bb0055) Jamphel (10.1016/j.rcsop.2022.100156_bb0035) 2018; 6 Tshering (10.1016/j.rcsop.2022.100156_bb0030) Ministry of Health (10.1016/j.rcsop.2022.100156_bb0015) Koffman (10.1016/j.rcsop.2022.100156_bb0020) 2020; 113 Bhuyan (10.1016/j.rcsop.2022.100156_bb0050) 2021; 397 Krause (10.1016/j.rcsop.2022.100156_bb0065) 2020; 383 Chejor (10.1016/j.rcsop.2022.100156_bb0045) 2018; 6 Chejor (10.1016/j.rcsop.2022.100156_bb0060) 2022 World Health Organization (10.1016/j.rcsop.2022.100156_bb0005) Drug Regulatory Authority (10.1016/j.rcsop.2022.100156_bb0040) LeVine (10.1016/j.rcsop.2022.100156_bb0010) 2020; 102 Stringer (10.1016/j.rcsop.2022.100156_bb0025) 2021; 123 |
| References_xml | – ident: 10.1016/j.rcsop.2022.100156_bb0030 – volume: 6 start-page: 35 issue: 2 year: 2018 ident: 10.1016/j.rcsop.2022.100156_bb0035 article-title: Evolution of medicines regulatory system in Bhutan: history, status and challenges publication-title: J Reg Sci – volume: 383 issue: 19 year: 2020 ident: 10.1016/j.rcsop.2022.100156_bb0065 article-title: Emergency use authorization of Covid vaccines - safety and efficacy follow-up considerations publication-title: N Engl J Med doi: 10.1056/NEJMp2031373 – volume: 6 start-page: 54 issue: 2 year: 2018 ident: 10.1016/j.rcsop.2022.100156_bb0045 article-title: Regulation of medicines in Bhutan: current status, challenges and opportunities publication-title: IJDRA. doi: 10.22270/ijdra.v6i2.243 – volume: 123 year: 2021 ident: 10.1016/j.rcsop.2022.100156_bb0025 article-title: Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder publication-title: J Subst Abuse Treat doi: 10.1016/j.jsat.2020.108263 – ident: 10.1016/j.rcsop.2022.100156_bb0055 – ident: 10.1016/j.rcsop.2022.100156_bb0015 – year: 2022 ident: 10.1016/j.rcsop.2022.100156_bb0060 article-title: Role of hospital drivers during the COVID-19 pandemic in National Referral Hospital, Bhutan [published online ahead of print, 2022 Jun 22] publication-title: Asia Pac J Public Health – volume: 113 start-page: 211 issue: 6 year: 2020 ident: 10.1016/j.rcsop.2022.100156_bb0020 article-title: Uncertainty and COVID-19: how are we to respond? publication-title: J R Soc Med doi: 10.1177/0141076820930665 – volume: 397 start-page: 1611 issue: 10285 year: 2021 ident: 10.1016/j.rcsop.2022.100156_bb0050 article-title: Experts criticise India's complacency over COVID-19 publication-title: Lancet. doi: 10.1016/S0140-6736(21)00993-4 – volume: 102 start-page: 1205 issue: 6 year: 2020 ident: 10.1016/j.rcsop.2022.100156_bb0010 article-title: Case report: the first case of COVID-19 in Bhutan publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.20-0259 – ident: 10.1016/j.rcsop.2022.100156_bb0005 – ident: 10.1016/j.rcsop.2022.100156_bb0040 |
| SSID | ssj0002794070 |
| Score | 2.2159765 |
| Snippet | Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was... Summary Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 100156 |
| SubjectTerms | COVID-19 pandemic Drug regulatory authority Emergency use authorization Medical products Vaccines |
| Title | Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan |
| URI | https://www.proquest.com/docview/2692756902 https://pubmed.ncbi.nlm.nih.gov/PMC9284528 https://doaj.org/article/5263e9ea73bd4249bd1d29dff21fb947 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqTr1UfVB1gSIjIU4bNevEduZYKAiQ2qIKEDfLT7EIErSPSvvvO7Z3YXOBS6-Oozieseab8cw3hOwHj2YxCEDkxssishEWTeNMITWAZroEo2Mc8ucvcXpVn9_wm7VWXzEnLNMD5437xpmoPHgtK-Nq9BWMGzkGLgQ2CgbqVEeONm_NmbpL12mAnkoMsKABkgWTQqwoh1Jy18ROu8hWyVgiIYrtq9fMUmLv70HOfsLkmgU6eU_eLaEj_Z6X_IG88e1HcnCRuacXQ3r5XEo1HdIDevHMSr34RK7_5K7z3WRBQ2TBTFmx6CdT3TqqU99EOuvo0e_rsx_FCOhfHIs58TRXMlJEivQxhpwfxpaOW3p4O0dguUmuTo4vj06LZVOFwqInNis0N2C5NUIEw0VtDCBi0rwxUAZdof23rqw44g4bRpqXtXFSlEai12e5jqf5M9lou9Z_IbR2YE3lg5SIa1zjGvBlqL2X0iAMhTAgbLWnyi4Zx2Pji3u1Si27U0kQKgpCZUEMyPDppcdMuPHy9MMorKepkS07DaAOqaUOqdd0aED2VqJWeLrilYlufTefKiYg8uNDyQZE9nSg98X-k3Z8m3i6AU0_Z83W_1jiNnkb_zpnt-2Qjdlk7r8iHJqZ3aT5uylO9Q88TgnN |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Regulatory+flexibilities+and+access+to+COVID-19+vaccines+during+the+pandemic+in+Bhutan&rft.jtitle=Exploratory+research+in+clinical+and+social+pharmacy&rft.au=Dawa+Tshering&rft.au=Pelden+Chejor&rft.date=2022-09-01&rft.pub=Elsevier&rft.issn=2667-2766&rft.eissn=2667-2766&rft.volume=7&rft.spage=100156&rft_id=info:doi/10.1016%2Fj.rcsop.2022.100156&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5263e9ea73bd4249bd1d29dff21fb947 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2667-2766&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2667-2766&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2667-2766&client=summon |